Vanessa Feltz, 63, jokes 'looking gaunt is fantastic' as she joins Lizzie Cundy, 57, to discuss weight loss jabs after news Mounjaro cost is set to double
The former This Morning presenter, 63, has long been open about her struggles with her weight, which have seen her fluctuate between a size 10 and 22.
She previously described the emotional rollercoaster of dieting as soul-destroying and has shared her experiences with gastric band surgery.
Now, in a clip from her show shared on Instagram, Vanessa and Lizzie, 57, offered their thoughts on the growing trend of weight loss jabs.
Lizzie said: 'You can tell some celebrities that are going too far on it, because they are looking gaunt… and you don't want to look like that.'
Vanessa quipped: 'I always want to look it. I'm desperate to look gaunt. I've always wanted to look gaunt.
'I think being gaunt would be a fabulous look having been fat for so many years. I think gaunt would just be fantastic.'
Mounjaro price increases
Mounjaro®▼ (tirzepatide) KwikPen® Dose Current UK List Price New UK List Price (From September)
2.5mg £92 £133
5mg £92 £180
7.5mg £107 £255
10mg £107 £255
12.5mg £122 £330
15mg £122 £330
Lizzie replied: 'But I don't think it's good when you hear these stories that it isn't always perfect having these jabs and you really got to know your own body and if it doesn't feel right, don't keep doing it.
'You know, there are other ways. And I think it's really important we hear the other side.'
'I totally agree,' Vanessa said.
It comes after Mounjaro manufacturer Lilly sparked panic among slimmers on Thursday after revealing it would more than double the price of the drug in the UK.
The US pharmaceutical giant announced the cost would soar from September 1, with the wholesale price of a month's supply of the highest dose rising from £122 to £330.
Lilly claimed it had initially launched Mounjaro in the UK at a price 'significantly below the European average to prevent delays in NHS availability' but that this must now change 'to ensure fair global contributions to the cost of innovation'.
The announcement, however, does not affect the price the NHS pays, as the service has negotiated a heavily discounted rate for those getting the drug on prescription.
But there are thought to be around 1.5 million people on weight loss drugs in the UK with more than half of them on Mounjaro—and estimates suggest nine in 10 pay for these drugs privately.
She added height to her slender frame with a pair of hot pink heels and carried her belongings in a pink Dior tote bag
After the show wrapped up, Lizzie put on a leggy display in a pink floral shirt mini dress as she left the studio.
She added height to her slender frame with a pair of hot pink heels and carried her belongings in a pink Dior tote bag.
The star completed her look with a stylish pair of sunglasses and appeared in good spirits as she headed to her next destination.
It comes after Lizzie's son married his long-term partner in Italy.
She was among close family and friends last month as Josh Miller exchanged vows with fiancée Martina Bassenger, a creative director for London based production company Sons of Rigor Films.
With Venice serving as an appropriately romantic backdrop, the happy couple - who met five years ago - looked stunning as they posed for photos with their parents shortly after the ceremony.
Martina opted for traditional white on the day, with the brunette walking the aisle in a custom floor-length gown and matching veil.
Meanwhile Josh, an actor and producer, chose a smart two piece suit from Nathan Palmer Bespoke Tailors, offset with a white dress shirt and bow tie.
Sharing an array of photos from the wedding on social media, she wrote: 'My boy only got married!…. I'm so proud I could burst!! Here's to the most beautiful couple Josh and Martina.. I've not stopped crying with joy.'
The weekend provided a reunion of sorts, with the presenter accompanied by ex-husband Jason Cundy - the groom's father - for an additional series of photos as the reception spilled over into the evening.
Radio broadcaster Cundy, a former footballer who played as a centre-back for Chelsea, Tottenham Hotspur and Ipswich Town before retiring in 2000, opted for a cream linen suit as he watched his son exchange vows.
Lizzie previously discussed the breakdown of her marriage during an appearance on Vanessa Feltz's Channel 5 show in May.
The presenter married Jason in 1994, with the couple welcoming two children before divorcing in 2010.
'At the time it broke my heart,' she told Feltz. 'As I said, I think I had a breakdown, I didn't eat, I lost an incredible amount of weight. I was very upset and Vanessa you were there and supporting me very much.'
However, she explained that she has been able to move past the hurt and has since built a strong friendship with her ex-husband.
She added: 'But life moves on and I say to everyone, make friends. There's no point being bitter and angry and that does go. And when I see him now, I don't think of that at all.'
The truth behind new diet drug craze - Hollywood is hooked on it, and social media is fanning demand for the latest weight-loss 'miracle'
Over the summer I was lucky enough to be invited to a 60th birthday at which the after-dinner entertainment was a private performance by one of the UK's leading male pop stars. More eye-popping than the actual show, though, was how incredible said star looked. He was a mere shadow of his former self, prancing around the stage in a silver catsuit. His secret? Semaglutide, or Ozempic as it is branded, a new diet drug that everybody – but everybody, darling, including one of the world's most famous supermodels – is apparently taking.
Originally developed to treat type 2 diabetes, it is used off-label (for a purpose other than that for which it was licensed) in both the US and the UK to treat obesity. In research conducted by its billionaire manufacturer, the Danish-based pharmaceutical company Novo Nordisk, patients lost an average of 17 per cent of their overall body weight over 68 weeks. This compares with five to nine per cent for 'oldschool' anti-obesity drugs such as Metformin.
Only available in the UK on the NHS if you have type 2 diabetes, Ozempic can be obtained through a private doctor, and if you are willing to take it without medical supervision – not recommended by doctors (see panel) – you can get it online through various weight-loss programmes. It is sometimes taken in tablet form but more commonly as an injection.
Predictably, Hollywood has been aware of Ozempic for a lot longer than us – Variety magazine recently quipped that the drug deserved its own thank-you speech at the Emmys, as so many stars on the podium had obviously been taking it. Elon Musk raved about its more powerful sister drug, Wegovy, on Twitter; Kim Kardashian, it is hotly rumoured, used semaglutide to lose 16lb in order to fit into Marilyn Monroe's dress for the Met Ball. On TikTok the hashtag #ozempic has had more than 285 million views.
Thanks to the hype, there has been a surge in demand, causing shortages on both sides of the Atlantic, with a backlash against influencers and celebrities hogging supplies ahead of desperate diabetes sufferers. Predictably, Big Pharma has come up with an alternative – tirzepatide (brand name Mounjaro), manufactured by Eli Lilly – but it has yet to be approved by the US Food & Drug Administration for weight loss.
Novo Nordisk has issued a statement to say its supplies will be replenished by the end of the year, but it hasn't quelled anxiety. At least two middle-aged male friends of mine who started using it in September are getting themselves in a twist about being caught short before the holidays. As one private London GP remarked to me: 'It's like the H RT panic last spring.'
So what exactly is this drug? Semaglutide belongs to a class called GLP-1 agonists, which not only regulate blood sugar but, as was discovered about a decade ago, also mimic the gut hormones that regulate our appetites – the ones that tell the brain when we are hungry or full. There are, of course, side effects: acid reflux, nausea, exacerbation of IBS symptoms and fatigue (but much less so than in earlier GLP-1 agonists such as Saxenda), as well as pancreatitis, gallstones and, in very high doses, it has caused thyroid tumours in rats. Meanwhile, when you stop using it the effect wears off immediately and in some cases it won't work at all.
'I would describe semaglutide as an example of very smart science,' says leading consultant endocrinologist Dr Efthimia Karra from her private practice off London's Harley Street. 'But it is not a panacea for everyone. Around a fifth of users do not respond to it. This is because the human body favours weight gain, thus when you lose weight the body will do anything to revert to its highest BMI. The heavier you are the harder it is to lose weight. If a patient has made no progress in three months, I will take them off it.'
Banker's wife Laura, a native New Yorker in her mid-50s who had hovered between decades, started using it in January. 'The Paleo diet, 5:2, CBT, NLP, bootcamp, diet delivery services – I've tried them all,' she says from the family home in Hampshire, 'and I've always yo-yoed right back. After my last annual checkup I seriously contemplated giving up. Then my doctor suggested semaglutide.'
After only a month she noticed her clothes had become looser. From then on, the weight started dropping off. 'The strange thing was, I wasn't eating anything different. I just couldn't physically have seconds any more, and the idea of pudding after a full meal had lost its allure.' Three months on, she is two stone lighter ‒ though occasionally she suffers heartburn if she eats too late at night or drinks alcohol ‒ and when we spoke in autumn, she was looking forward to losing another stone by Christmas.
'There is a niggling voice that tells me it is both risky and lazy to take a drug to lose weight, and I worry that it will all pile on again if I stop taking it. But if it does, I will seriously consider taking it indefinitely.'
Private London GP Dr Martin Galy has been prescribing semaglutide for about a year to clients who cannot lose the weight they gained in menopause. He has seen it have a transformational effect, too, on much younger women who suffer polycystic ovary syndrome. 'PCOS sufferers are difficult to treat, and you can imagine how body image plays a very important part when it comes to self-esteem.'
But according to Tom Sanders, professor of nutrition and dietetics at King's College London, it is not a magic bullet. Commenting on a study on semaglutide published in The New England Journal of Medicine in 2021, he says, 'The challenge post-weight loss is to prevent a regain in weight,' he wrote. It may prove to be useful in the short term, but 'public health measures that encourage behavioural changes such as regular physical activity and moderating dietary energy intake are still needed'.
That said, given our rising national obesity statistics and the escalation in accompanying health issues such as heart failure, cancer and obstructive sleep apnoea clogging up hospital beds, we're going to need something. Semaglutide may be the rich person's drug today, but might it be approved for more widespread use? Only time will tell.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
an hour ago
- The Guardian
The Guardian view on regulating cosmetic procedures: rogue operators must be tackled, but aren't the only problem
The enormous popularity of beauty treatments, including dermatological fillers and Botox injections, is not solely an issue for health regulators. Changing norms and aspirations about appearances, and the way that these are marketed mainly to women and girls, are a cultural and economic phenomenon that requires wider consideration. While attitudes to these procedures and aesthetics vary, many people – including some cosmetic surgeons – are concerned that younger women account for a growing share of a highly lucrative and growing market. The death last year of 33-year-old Alice Webb in Gloucestershire, after a non-surgical Brazilian butt lift, as well as multiple reports of injuries, and the deaths of at least 28 women who have travelled to Turkey for cosmetic treatments, have increased the pressure on ministers to tighten the law. Wes Streeting's announcement of new licence requirements for UK businesses, and tighter regulation of higher-risk treatments, is probably overdue. The Chartered Trading Standards Institute recently warned that untrained people have given cosmetic injections in public toilets and hotels. Altering the law in order to exclude such 'rogue operators' ought to make high streets and the internet – where many clinics advertise – safer. Talking about the risks, as the health secretary has been doing, and holding a consultation on proposed changes, may have the beneficial effect of raising awareness even before changes are introduced. But councils will need resources if they are to be expected to enforce new rules by issuing licences, checking premises and so on. As in many other areas of economic activity, the law on its own is unlikely to be enough. Mechanisms are needed to ensure that businesses comply. It is already illegal to administer Botox or dermal fillers to children in England – although, worryingly, it is still allowed in Wales and Scotland. Mr Streeting's announcement that rules regarding children will be tightened further is particularly welcome. Strenuous efforts should be made to place them off limits for the industry as a whole. The reported preoccupation of some children with anti-ageing products is not healthy and should be discouraged. Mr Streeting did not refer to the cost to the NHS if cosmetic procedures go wrong, when announcing plans to tighten the law. But Karin Smyth, one of his ministers, has raised this. And Prof Sir Stephen Powis, who was NHS England's national medical director until last month, made the same point specifically in relation to butt lifts – the cosmetic procedure with the highest death rate of all. Ministers should expect pushback even though many experts, including plastic surgeons, favour tighter rules. The pro-growth mood of the Treasury means proposals for new regulations are unlikely to be smiled upon there. The more restrictive approach being proposed for England will also do nothing to prevent surgical tourism and could even increase it, if tighter regulation of the domestic industry results in higher prices. The gap in safeguards that allows foreign cosmetic surgery providers to market directly to the public needs to be addressed separately, which the government has begun to recognise. There is no single or instant fix. But by cracking down on cowboy operators, ministers will send a message that appearance-altering injections and other invasive treatments must be treated seriously. They are a different order of activity from applying makeup or painting nails. Do you have an opinion on the issues raised in this article? If you would like to submit a response of up to 300 words by email to be considered for publication in our letters section, please click here.
Times
2 hours ago
- Times
Obese to get soups and shakes diet instead of weight-loss jabs
Low-calorie soups and shakes are to be prescribed to thousands of overweight people in Scotland in an attempt to reduce their dependence on expensive weight-loss drugs and provide longer-lasting health benefits. From January, 3,000 patients who have been newly diagnosed with type 2 diabetes will be recruited for a clinical trial. About 300,000 Scots live with type 2 diabetes, a condition commonly linked to obesity, in which badly regulated blood sugar levels can increase the risk of heart disease, kidney disease, strokes or nerve conditions. About 10,000 of them are being treated with weight-loss drugs such as Ozempic, Wegovy and Mounjaro, with injections costing the NHS £3,000 a year. The estimated annual bill of £30 million is expected to rise as manufacturers raise prices. NHS chiefs believe that not only will the soups and shakes plan be less expensive, it will also bring longer-term health benefits. In the Total Diet Replacement (TDR) plan, to be rolled out over three years, patients who have recently been diagnosed with type 2 diabetes and are deemed eligible will be given low-calorie substitutes for their breakfast, lunch and dinner. The replacement meals, containing a maximum of 900 calories a day, will be delivered to patients for between three and five months. • What to do now Mounjaro's hiking its prices, by an obesity expert After this initial period, normal food will be reintroduced, but with guidance given on healthy meals through online consultations and an app. The ambition is for patients to lose up to 10 per cent of their body weight over a year. Doctors are also optimistic that up to 40 per cent of the trial participants will achieve remission from type 2 diabetes within a year. There are fears that the weight lost through injections — which work by suppressing the appetite — may last only as long as the patient is taking the drug. By contrast, the effects of diet changes should prove more long-lasting and cost effective, NHS officials believe. The TDR scheme is set to cost £5.6 million for 3,000 patients, a one-off cost of about £1,866 per person. Doctors hope the plan will help patients to fundamentally alter their diet and lifestyle. A spokesman for the Scottish government said: 'We anticipate that around 35 to 40 per cent will achieve remission from type 2 diabetes at the end of their first year on the programme, with a majority of patients benefiting from a clinically significant average weight loss of 10 per cent.' This would lead to reductions in blood pressure and contribute to a reduced risk of cardiovascular disease. He added: 'We will measure impact by the number of patients recruited into this programme, the number who achieve remission and the number with clinically significant weight loss.'
The Guardian
3 hours ago
- The Guardian
The Guardian view on regulating cosmetic procedures: rogue operators must be tackled, but aren't the only problem
The enormous popularity of beauty treatments, including dermatological fillers and Botox injections, is not solely an issue for health regulators. Changing norms and aspirations about appearances, and the way that these are marketed mainly to women and girls, are a cultural and economic phenomenon that requires wider consideration. While attitudes to these procedures and aesthetics vary, many people – including some cosmetic surgeons – are concerned that younger women account for a growing share of a highly lucrative and growing market. The death last year of 33-year-old Alice Webb in Gloucestershire, after a non-surgical Brazilian butt lift, as well as multiple reports of injuries, and the deaths of at least 28 women who have travelled to Turkey for cosmetic treatments, have increased the pressure on ministers to tighten the law. Wes Streeting's announcement of new licence requirements for UK businesses, and tighter regulation of higher-risk treatments, is probably overdue. The Chartered Trading Standards Institute recently warned that untrained people have given cosmetic injections in public toilets and hotels. Altering the law in order to exclude such 'rogue operators' ought to make high streets and the internet – where many clinics advertise – safer. Talking about the risks, as the health secretary has been doing, and holding a consultation on proposed changes, may have the beneficial effect of raising awareness even before changes are introduced. But councils will need resources if they are to be expected to enforce new rules by issuing licences, checking premises and so on. As in many other areas of economic activity, the law on its own is unlikely to be enough. Mechanisms are needed to ensure that businesses comply. It is already illegal to administer Botox or dermal fillers to children in England – although, worryingly, it is still allowed in Wales and Scotland. Mr Streeting's announcement that rules regarding children will be tightened further is particularly welcome. Strenuous efforts should be made to place them off limits for the industry as a whole. The reported preoccupation of some children with anti-ageing products is not healthy and should be discouraged. Mr Streeting did not refer to the cost to the NHS if cosmetic procedures go wrong, when announcing plans to tighten the law. But Karin Smyth, one of his ministers, has raised this. And Prof Sir Stephen Powis, who was NHS England's national medical director until last month, made the same point specifically in relation to butt lifts – the cosmetic procedure with the highest death rate of all. Ministers should expect pushback even though many experts, including plastic surgeons, favour tighter rules. The pro-growth mood of the Treasury means proposals for new regulations are unlikely to be smiled upon there. The more restrictive approach being proposed for England will also do nothing to prevent surgical tourism and could even increase it, if tighter regulation of the domestic industry results in higher prices. The gap in safeguards that allows foreign cosmetic surgery providers to market directly to the public needs to be addressed separately, which the government has begun to recognise. There is no single or instant fix. But by cracking down on cowboy operators, ministers will send a message that appearance-altering injections and other invasive treatments must be treated seriously. They are a different order of activity from applying makeup or painting nails. Do you have an opinion on the issues raised in this article? If you would like to submit a response of up to 300 words by email to be considered for publication in our letters section, please click here.
